TSX runs higher on rate cut expectations
On July 29, 2025, Vanessa Carle, Secretary of Lexaria Bioscience Corp (NASDAQ:LEXX), purchased 750 common shares of the company. The shares were bought at $0.91, totaling $682, amid a significant 75% decline in share price over the past year. According to InvestingPro analysis, the stock is currently trading below its Fair Value, suggesting potential upside opportunity.
Following the transaction, Carle directly owns 750 common shares of Lexaria Bioscience Corp.
Carle also holds options to acquire 75,000 common shares of Lexaria Bioscience Corp. These options are exercisable at prices ranging from $1.04 to $3.00, with expiration dates between 2026 and 2030.
In other recent news, Lexaria Bioscience Corp. announced interim results from its Phase 1b GLP-1-H24-4 study in Australia, focusing on the DehydraTECH-semaglutide and DehydraTECH-tirzepatide arms. The company also reported that its DehydraTECH technology can reduce side effects in leading GLP-1 weight loss and diabetes drugs, addressing significant challenges with patient retention due to adverse effects. Lexaria has expanded its international patent portfolio to 50, with new patents including one in Australia for treating epilepsy, which will expire in 2044.
Additionally, Lexaria is advancing its drug delivery technology through a collaboration with a pharmaceutical company, referred to as PharmaCO. This collaboration includes completed pre-clinical studies under a Material Transfer Agreement, with further data expected in Q3 2025. H.C. Wainwright adjusted its price target for Lexaria Bioscience, lowering it to $4.00 from $5.00 while maintaining a Buy rating, following the company’s interim study results. Previously, H.C. Wainwright had also lowered the price target from $7.00 to $5.00 after positive partial results from a human pilot study comparing DehydraTECH-liraglutide to Saxenda. These developments highlight Lexaria’s ongoing efforts to enhance its DehydraTECH technology and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.